Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $26,330,000 | $16,173,000 | $4,605,000 | $22,246,000 |
| Dep. & Amort. | $20,099,000 | $17,888,000 | $19,409,000 | $10,954,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$3,896,000 | -$32,574,000 | -$13,747,000 | -$3,102,000 |
| Other Non-Cash | -$19,132,000 | $6,725,000 | -$7,723,000 | -$7,969,000 |
| Operating Cash Flow | $23,401,000 | $8,212,000 | $2,544,000 | $22,129,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$28,736,000 | -$37,851,000 | -$30,469,000 | -$13,576,000 |
| Net Acquisitions | $0 | -$1,570,000 | -$1,484,000 | -$45,405,000 |
| Inv. Purchases | -$203,000 | -$50,000 | -$301,000 | -$1,000 |
| Inv. Sales/Matur. | $0 | $0 | $34,000 | $18,000 |
| Other Inv. Act. | -$2,348,000 | -$923,000 | $1,936,000 | -$765,000 |
| Investing Cash Flow | -$31,287,000 | -$40,394,000 | -$30,284,000 | -$59,729,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $15,376,000 | $38,560,000 | $20,883,000 | $49,114,000 |
| Stock Issued | $0 | $0 | $0 | $21,000 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$2,953,000 | -$2,952,000 | -$3,100,000 | -$2,411,000 |
| Other Fin. Act. | $9,144,000 | -$201,000 | -$302,000 | -$184,000 |
| Financing Cash Flow | $21,567,000 | $35,407,000 | $17,481,000 | $46,540,000 |
| Forex Effect | $1,916,000 | $2,167,000 | $1,685,000 | $975,000 |
| Net Chg. in Cash | $15,810,000 | $5,393,000 | -$8,573,000 | $9,915,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $29,650,000 | $24,257,000 | $32,830,000 | $22,915,000 |
| End Cash | $45,460,000 | $29,650,000 | $24,257,000 | $32,830,000 |
| Free Cash Flow | -$7,822,000 | -$31,113,000 | -$27,925,000 | $8,553,000 |